MSCI signals $3B share repurchase authorization while accelerating AI-driven product launches and expanding client segments

Get key insights from MSCI’s Q3 2025 earnings: strong growth, $3B share buybacks, AI-driven innovation, and outlook for sustained value.
Novartis

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc) Core operating income margin 1 was ...